ARS Pharmaceuticals Inc. (SPRY), undeterred by its previous regulatory setback, has mounted a resolute second effort to secure FDA approval for its investigational product neffy.
Having completed the required studies and resubmitted its New Drug Application for neffy with additional data and refinements, the company is back at the FDA's doorstep, determined to cross the elusive finish line to commercialization.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.